This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Beijing University of Technology, Monash University. Active years: 2023-2025.
Company Filing History:
Years Active: 2023-2025
Title: Mark Sleeman: Innovator in Human Thrombin Receptor Research
Introduction
Mark Sleeman is a notable inventor based in Clayton, Australia. He has made significant contributions to the field of biomedical research, particularly in the area of human protease activated receptors. With a total of two patents to his name, Sleeman's work focuses on the development of binding proteins that interact with the human thrombin receptor, PAR4.
Latest Patents
Sleeman's latest patents include innovative approaches to binding proteins for the human thrombin receptor, PAR4. The disclosures detail the development of anti-PAR4 binding proteins, which serve as antagonists to human PAR4. These advancements have potential applications in various therapeutic methods and uses, highlighting the importance of his research in the medical field.
Career Highlights
Throughout his career, Mark Sleeman has worked with prestigious institutions such as Beijing University of Technology and Monash University. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Sleeman has collaborated with Justin Hamilton, further enhancing the scope and impact of his research endeavors. Their combined expertise has led to advancements in understanding the mechanisms of human thrombin receptors.
Conclusion
Mark Sleeman's contributions to the field of biomedical research, particularly through his patents on binding proteins for the human thrombin receptor, underscore his role as an influential inventor. His work continues to pave the way for future innovations in medical therapies.